Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis

Azidus Brasil71 enrolled

Overview

To evaluate the efficacy of the combination of mometasone furoate 0.1% and Salicylic Acid 5% in patients of both sexes who presented clinical symptoms of psoriasis of mild to moderate.

Phase III clinical trial, systematic sampling, open-label study that evaluated the efficacy of the combination of mometasone furoate 0.1% and 5% salicylic acid in 71 patients with lesions of mild to moderate psoriasis treated for up to 45 days or less than this, at the discretion of the investigator. The results were statistically analyzed and investigational data and their conclusions are referred to in this report.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Psoriasis

Interventions

memotasone + salicylic acidDRUG

mometasone 0,1% + salicylic acid 5%.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults of both sexes, regardless of color or social class; * Age 18 or older, with good mental health; * Psoriasis patients with mild to moderate; * Patients who agreed to participate and signed the * Clarified (appendix); * Patients who agreed to return for follow-up visits. Exclusion Criteria: * Patients who were making use of biologics, corticosteroids or nonsteroidal anti-inflammatory and non-steroid, or who made use of these topical medications until 15 days before inclusion or 30 days before inclusion when the administration was orally; * Patients who were exposed to the sun 15 days before the study began or during the course of the same; * Patients who were making use of acetaminophen; * Patients who did not agree to the terms described in the IC informed consent, - Patients who also had psoriatic plaques of skin disorders caused by fungi or bacteria and they were making use of antibiotic or antifungal; * Lions and other types of skin damage that was not psoriasis; * Pregnant and nursing women; * Patients using oral anticoagulants.

Locations (1)

LAL Clinica Pesquisa e Desenvolvimento Ltda.

Valinhos, São Paulo, Brazil

Outcomes

Primary Outcomes

To assess the safety in use as primary end point and end point as effectively isolated secondary association in patients with plaque psoriasis of mild to moderate.

Patients will visit the center at weeks 0, 1, 2, 4 and 6 totaling 45 days. Parameters will be evaluated for erythema, plaque size, scaling, itching, thickness of the lesion as well as recording and analysis of adverse effects from treatments.

Time frame: 45 days of treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.